Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison

IMPORTANCE: Thyroid eye disease can be a debilitating autoimmune disorder characterized by progressive proptosis or diplopia. Teprotumumab has been compared with placebo in randomized clinical trials, but not with intravenous methylprednisolone (IVMP), which sometimes is used in clinical practice fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S., Dailey, Roger, Subramanian, Prem S., Barbesino, Giuseppe, Ugradar, Shoaib, Batten, Ryan, Qadeer, Rana A., Cameron, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855315/
https://www.ncbi.nlm.nih.gov/pubmed/35175308
http://dx.doi.org/10.1001/jamaophthalmol.2021.6284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855315/
https://www.ncbi.nlm.nih.gov/pubmed/35175308
http://dx.doi.org/10.1001/jamaophthalmol.2021.6284

Ejemplares similares